Tempest Therapeutics, Inc.
10-K
March 30, 2026
Key Highlights
- Lead CAR-T drug TPST-2003 achieved a 100% response rate in a 12-patient multiple...
- Strategic partnerships with the National Cancer Institute and Novatim reduce cli...
- Strong cash position of $58 million provides an operational runway through the s...
Read Analysis
🤖 AI Generated